Leerink Partnrs Estimates Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for shares of Zura Bio in a report issued on Sunday, November 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.77) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.

ZURA has been the subject of several other research reports. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a research report on Friday, November 14th. Oppenheimer reduced their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, August 15th. HC Wainwright decreased their price target on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research note on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. Finally, Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Trading Up 1.3%

Shares of NASDAQ:ZURA opened at $3.80 on Wednesday. Zura Bio has a 12-month low of $0.97 and a 12-month high of $4.68. The stock’s 50-day moving average price is $3.58 and its 200-day moving average price is $2.21. The stock has a market capitalization of $247.08 million, a P/E ratio of -5.85 and a beta of 0.24.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02).

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently added to or reduced their stakes in the stock. Scientech Research LLC purchased a new position in Zura Bio during the third quarter valued at approximately $45,000. Forefront Wealth Partners LLC bought a new stake in shares of Zura Bio during the 3rd quarter valued at $93,000. Squarepoint Ops LLC purchased a new position in shares of Zura Bio during the 3rd quarter valued at $109,000. Qube Research & Technologies Ltd bought a new position in Zura Bio in the 3rd quarter worth $138,000. Finally, Savant Capital LLC boosted its holdings in Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.